Summary of Study ST001495
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001013. The data can be accessed directly via it's Project DOI: 10.21228/M8RH7J This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST001495 |
Study Title | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
Study Type | untargeted metabolomics |
Study Summary | Effect of antibiotics on fecal microbiome and metabolome |
Institute | University of California, Davis |
Department | College of Biological Sciences |
Laboratory | West Coast Metabolomics Center |
Last Name | Paglia |
First Name | Kelly |
Address | 451 Health Sciences Drive, Room 1313 |
kpaglia@ucdavis.edu | |
Phone | 5307528129 |
Submit Date | 2020-09-24 |
Raw Data Available | Yes |
Raw Data File Type(s) | cdf |
Analysis Type Detail | GC-MS |
Release Date | 2020-10-13 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR001013 |
Project DOI: | doi: 10.21228/M8RH7J |
Project Title: | Effects of Synbiotic Administration on Fecal Microbiome and Metabolomic Profiles of Dogs receiving Antibiotics |
Project Type: | Double-blind randomized controlled trial |
Project Summary: | The purpose of this study was to compare the fecal microbiome and metabolome of dogs administered enrofloxacin and metronidazole, followed by either a placebo or a bacterial/yeast synbiotic combination, for 21 days with reevaluation 8 weeks after treatment. Fecal samples were collected on days 5-7 (baseline), 26-28, and 82-84. The fecal microbiome was analyzed by qPCR and sequencing of 16S rRNA genes; time-of-flight mass spectrometry was used to determine metabolomic profiles. Split plot repeated measures ANOVAs were used to compare results between treatment groups. P < 0.05 was considered significant, with Benjamini & Hochberg’s False Discovery Rate used to adjust for multiple comparisons. Alpha diversity metrics differed significantly over time in both treatment groups, with incomplete recovery by days 82-84. Beta diversity and the dysbiosis index differed significantly over time and between treatment groups, with incomplete recovery at days 82-84 for dogs in the placebo group. Significant group-by-time interactions were noted for 15 genera, including Adlercreutzia, Bifidobacterium, Slackia, Turicibacter, Clostridium, [Ruminococcus], Erysipelotrichaceae_g_, [Eubacterium], and Succinivibrionaceae_g_. Group and time effects were present for six genera, including Collinsella, Ruminococcaceae_g_, and Prevotella. Metabolite profiles differed significantly by group-by-time, group, and time for 28, 20, and 192 metabolites, respectively. These included short-chain fatty acid, bile acid, tryptophan, sphingolipid, benzoic acid, and cinnaminic acid metabolites, as well as fucose and ethanolamine. Changes in many taxa and metabolites persisted through days 82-84. |
Institute: | University of Tennessee |
Department: | College of Veterinary Medicine |
Laboratory: | Small Animal Clinical Sciences |
Last Name: | Whittemore |
First Name: | Jacqueline |
Address: | 2407 River Drive, Knoxville TN 37996 |
Email: | jwhittemore@utk.edu |
Phone: | 865-974-8387 |
Funding Source: | Nutramax Laboratories Veterinary Sciences, Inc., Lancaster, SC |